Our results showed that the levels of CD19(+)CD5(+) B cells was significantly decreased in moderate-to-severe CKD patients and IMT was increased in the lower levels of CD19(+)CD5(+) B cells, that could explain why patients with CKD exhibit accelerated development of atherosclerosis. This evidence concerns the gene CD5 and chronic kidney disease.